Hatsukami DK - Search Results

1

Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products.

Hatsukami DK, Lemmonds C, Zhang Y, Murphy SE, Le C, Carmella SG, Hecht SS. Hatsukami DK, et al. J Natl Cancer Inst. 2004 Jun 2;96(11):844-52. doi: 10.1093/jnci/djh163. J Natl Cancer Inst. 2004. PMID: 15173268 Clinical Trial.

2

Smokeless tobacco abstinence effects and nicotine gum dose.

Hatsukami D, Anton D, Keenan R, Callies A. Hatsukami D, et al. Psychopharmacology (Berl). 1992;106(1):60-6. doi: 10.1007/BF02253589. Psychopharmacology (Berl). 1992. PMID: 1738794 Clinical Trial.

3

Topographical features of smokeless tobacco use.

Hatsukami DK, Keenan RM, Anton DJ. Hatsukami DK, et al. Psychopharmacology (Berl). 1988;96(3):428-9. doi: 10.1007/BF00216076. Psychopharmacology (Berl). 1988. PMID: 3146780

4

Effects of behavioral and pharmacological treatment on smokeless tobacco users.

Hatsukami D, Jensen J, Allen S, Grillo M, Bliss R. Hatsukami D, et al. J Consult Clin Psychol. 1996 Feb;64(1):153-61. doi: 10.1037//0022-006x.64.1.153. J Consult Clin Psychol. 1996. PMID: 8907095 Clinical Trial.

5

Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation.

Hecht SS, Carmella SG, Chen M, Dor Koch JF, Miller AT, Murphy SE, Jensen JA, Zimmerman CL, Hatsukami DK. Hecht SS, et al. Among authors: hatsukami dk. Cancer Res. 1999 Feb 1;59(3):590-6. Cancer Res. 1999. PMID: 9973205

6

Quantitation of 4-oxo-4-(3-pyridyl)butanoic acid and enantiomers of 4-hydroxy-4-(3-pyridyl)butanoic acid in human urine: A substantial pathway of nicotine metabolism.

Hecht SS, Hatsukami DK, Bonilla LE, Hochalter JB. Hecht SS, et al. Among authors: hatsukami dk. Chem Res Toxicol. 1999 Feb;12(2):172-9. doi: 10.1021/tx980214i. Chem Res Toxicol. 1999. PMID: 10027795

7

Characteristics of smokeless tobacco users seeking treatment.

Hatsukami DK, Jensen J, Boyle R, Grillo M, Bliss R. Hatsukami DK, et al. Addict Behav. 1999 Jul-Aug;24(4):551-7. doi: 10.1016/s0306-4603(98)00092-6. Addict Behav. 1999. PMID: 10466850

8

Treatment of spit tobacco users with transdermal nicotine system and mint snuff.

Hatsukami DK, Grillo M, Boyle R, Allen S, Jensen J, Bliss R, Brown S. Hatsukami DK, et al. J Consult Clin Psychol. 2000 Apr;68(2):241-9. J Consult Clin Psychol. 2000. PMID: 10780124 Clinical Trial.

9

Oral spit tobacco: addiction, prevention and treatment.

Hatsukami DK, Severson HH. Hatsukami DK, et al. Nicotine Tob Res. 1999 Mar;1(1):21-44. doi: 10.1080/14622299050011131. Nicotine Tob Res. 1999. PMID: 11072386 Review.

10

Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use.

Hecht SS, Carmella SG, Ye M, Le KA, Jensen JA, Zimmerman CL, Hatsukami DK. Hecht SS, et al. Among authors: hatsukami dk. Cancer Res. 2002 Jan 1;62(1):129-34. Cancer Res. 2002. PMID: 11782369

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

566 results

Search Page

Filters